Physician profile
Brock Jackson
NPI 1821093667
$1,733.34
in general payments reported to CMS, 2019-2025
23 companies · $149 in 2025
The $149 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $45.19 · 2021: $66.99 · 2022: $442 · 2023: $258 · 2024: $226 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $290.99 | 2019 | |
| Organon LLC | $265.57 | 2021-2025 | Nexplanon |
| Abbvie INC. | $162.98 | 2019-2022 | |
| Gynesonics, INC. | $150.13 | 2022 | |
| Hologic Sales and Service, LLC | $135.42 | 2020-2025 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
| Coopersurgical, INC. | $105.53 | 2019-2024 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $76.75 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $70.50 | 2023 | |
| Therapeuticsmd, INC. | $53.30 | 2019-2020 | |
| Myovant Sciences INC. | $48.60 | 2022 | |
| Merck Sharp & Dohme LLC | $47.58 | 2019 | |
| Minerva Surgical, INC | $45.81 | 2019-2023 | |
| Baxter Healthcare | $45.76 | 2024 | Perclot |
| Astellas Pharma US INC | $41.22 | 2023 | Veozah |
| Pfizer INC. | $39.76 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $34.07 | 2019 | |
| Dexcom, INC. | $21.25 | 2023 | Dexcom G6 Transmitter |
| Mylan Pharmaceuticals INC. | $17.42 | 2021 | |
| Boston Scientific Corporation | $16.98 | 2022 | |
| Millicent US INC | $16.91 | 2024 | Femring, Intrarosa |
| Exeltis, USA INC. | $16.56 | 2025 | Slynd |
| Daiichi Sankyo INC. | $16.13 | 2019 | |
| Solventum Corporation | $14.12 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brock Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.